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1. Introduction 
Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal cells that can be 
isolated from many adult tissues (Uccelli et al., 2008). Adult MSCs can be isolated from bone 
marrow, marrow aspirates, skeletal muscle, adipose tissue (Guilak et al., 2010), synovium 
and many other connective tissues (Barry, 2003). Due to their culture-dish adherence, they 
can be expanded in culture while maintaining their multipotency (Caplan, 2007). Their 
multipotency is an important property that allows them to differentiate into cells of the 
mesodermal lineage, giving rise to a range of specialized connective tissue cells including 
adipocytes, osteoblasts, chondrocytes and tenocytes as well as cells of other embryonic 
lineages (Figure 1) (Uccelli et al., 2008). MSCs have been isolated from humans and a variety 
of animal species including rodents, rabbits, dogs and horses. MSCs show considerable 
promise for use in repairing and rebuilding damaged or diseased mesenchymal tissues 
(Caplan, 2007). After in vivo administration, MSCs can induce peripheral tolerance and 
migrate to injured tissues where they have the capacity to exert immunosuppressive 
properties (Uccelli et al., 2007) and inhibit the release of pro-inflammatory cytokines and 
promote the survival of existing cells and the repair of damaged tissue (Uccelli et al., 2008). 
They are being clinically explored as a new therapeutic for treating a variety of immune-
mediated diseases (Parekkadan and Milwid, 2010). Thus, they have potential applications in 
tissue engineering and regenerative medicine and may represent an attractive option for 
bone, cartilage, tendon and ligament regeneration. 
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Fig. 1. Multipotency of mesenchymal stem cells (MSCs). MSCs can give rise to myocytes, 
chondrocytes, osteoblasts, tenocytes and a variety of other connective tissue cells 
This chapter focuses on the potential of MSCs as an alternative to cells derived from patient 
tissues in autologous transplantation and tissue engineering. The prospects of using MSCs 
in regenerative medicine strategies are discussed and the advantages and disadvantages of 
these cells in articular cartilage tissue engineering are summarized. There is currently little 
consensus on how MSCs are best isolated, identified and characterized. This is partly due to 
the paucity of standardized specific cell surface markers. Although MSCs cells have been 
isolated and expanded in culture, their use for therapeutic strategies requires protocols and 
technologies that have not yet been clinically trialled and perfected (Caplan, 2005). Also, 
there are no established guidelines from governmental and intergovernmental agencies for 
their use in clinical applications. Even if these guidelines existed, more research is needed to 
help understand their basic biology since the therapeutic effects afforded by MSC 
transplantation are likely to be short-lived and related to dynamic, paracrine interactions 
between MSCs and host cells (Parekkadan and Milwid, 2010). MSCs possess a fibroblastic 
morphology but the published literature suggests that there is no well-defined phenotype 
for these cells. More work is needed to characterise the phenotype of these cells. This 
chapter will also focus on the conceptual and practical difficulties associated with 
differentiating and preconditioning MSCs for subsequent survival in a physiologically harsh 
extracellular matrix, an environment that will be highly hypoxic, acidic, and nutrient 
deprived. Interestingly, published data suggests that MSCs better differentiate into 
chondrocytes in low oxygen environments. 
2. Increasing life expectancy and the growing burden of musculoskeletal and 
joint diseases 
For the past 160 years human life expectancy has consistently increased by a quarter of a 
year every year (Oeppen and Vaupel, 2002). It is predicted that life expectancy will continue 
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to increase by 2.5 years each decade, meaning that the western world's average life 
expectancy should reach and exceed 100 within the next 50 years (Oeppen and Vaupel, 
2002). The increase in life expectancy has been mainly due to the significant advances in 
medicine and healthcare. However, the increased longevity of humans has greatly expanded 
the elderly population in the western world and has resulted in the increased prevalence of 
a range of arthritic, rheumatic and musculoskeletal disorders, which are placing an ever-
greater socioeconomic burden on health systems around the world as the population ages. 
According to the World Health Organization (WHO)1, orthopaedic, rheumatic and 
musculoskeletal conditions comprise over 150 diseases and syndromes, which are usually 
progressive and associated with pain and disability. They can broadly be categorized as 
joint diseases, physical disability, spinal disorders, and conditions resulting from trauma. 
These conditions are leading causes of morbidity, giving rise to enormous healthcare 
expenditures and loss of productivity. Knowledge of the key determinants of disability in 
musculoskeletal conditions is critical for reducing their burden on the world's growing 
population (Oeppen and Vaupel, 2002; Weigl et al., 2008). 
The United Nations, the WHO and 37 other countries have proclaimed the years 2000-2010 
as the Bone and Joint Decade2 (McGowan, 2003; Woolf and Pfleger, 2003). This global 
initiative is intended to improve the lives of people with musculoskeletal disorders, such as 
arthritis, and to advance understanding and treatment of musculoskeletal disorders through 
prevention, education and research. The 10-year global initiative launched by the UN urges 
governments around the world to start taking action to draw attention to the growing 
pervasiveness and impact of musculoskeletal diseases and to reduce the social and financial 
burdens to society. Support for this global initiative will raise awareness of musculoskeletal 
health, stimulate research and improve people's quality of life. 
Musculoskeletal diseases are one of the major causes of disability around the world and 
have been a significant reason for the development of the Bone and Joint Decade (Brooks, 
2002; McGowan, 2003; Woolf and Pfleger, 2003). Rheumatoid arthritis (RA), osteoarthritis 
(OA), gout and back pain are important causes of disability-adjusted-life years in both the 
developed and developing world (Brooks, 2006). The Arthritis Foundation3 in the United 
States plays a key role in co-ordinating efforts during the Bone and Joint Decade as a 
supporter. Its aims are to: 
• Raise awareness and educate the world on the increasing societal impact of 
musculoskeletal injuries and disorders 
• Empower patients to participate in decisions about their care and treatment 
• Increase global funding for prevention activities and treatment research 
• Continually seek and promote cost-effective prevention and treatment of 
musculoskeletal injuries and disorders 
The major consequence of all forms of arthritis is joint dysfunction, disability, chronic pain, 
and significant morbidity. Aside from analgesics, there are currently no effective 
pharmacotherapies capable of restoring the structure and function of damaged synovial 
tissues in any form of arthritis. Consequently, there is an acute need for developing new 
tissue engineering and regenerative medicine strategies for arthritis. 
                                                 
1 http://www.who.int/en/ 
2 http://www.arthritis.org/bone-joint-decade.php  
3 http://www.arthritis.org/  
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3. The inflammatory component of musculoskeletal and joint diseases 
Many rheumatic diseases and arthritic conditions are essentially inflammatory disorders. 
The term “arthritis” characterizes a group of conditions involving damage to synovial joints. 
Arthritis literally means an inflammation (itis) of the joints (arthr). It involves pain, redness, 
heat, swelling and other harmful effects of inflammation within the joint. The most common 
form OA (also known as osteoarthrosis or degenerative joint disease) can result from trauma 
to the joint, infection of the joint, or simply as a consequence of ageing. Other forms of 
arthritis include psoriatic arthritis, and autoimmune diseases in which the body’s immune 
system attacks itself such as RA. Inflammation plays slightly different roles in OA and RA. 
Inflammation is primarily the result of OA but in RA it is the root cause. The major 
consequence of arthritis is pain and disability. Pain is a constant and daily feature in well-
established forms of the disease. Arthritis pain occurs due to inflammation that occurs 
around the joint, damage to the joint from disease, daily wear and tear of joint, muscular 
strains caused by movement against stiff, painful joints and fatigue. Disability in patients 
with arthritis is a consequence of degeneration in the joint and surrounding tissues and is 
further enhanced by inflammation-induced pain. 
4. Rheumatoid Arthritis (RA), Osteoarthritis (OA) and Lower Back Pain (LBP) 
The number of rheumatoid arthritis (RA) and osteoarthritis (OA) patients steadily rises as 
the elderly population grows in Western Europe, North America, and the rest of the 
developing world. RA, OA, and lower back pain (LBP) are important causes of disability 
adjusted-life years in both the developed and developing world (Brooks, 2006). Back and 
knee pain are common in the community and are likely to increase with the aging 
population (Brooks, 2006). Until recently OA was viewed as a ‘‘degenerative’’ or ‘‘wear-and 
tear’’ disease and held little interest for most clinicians. It is now accepted that the age 
related degeneration of articular cartilage as part of the clinical syndrome of OA is one of 
the most common causes of pain and disability in middle-aged and older people (Brooks, 
2006). RA, OA and LBP pain are among the major causes of disability and morbidity within 
the adult population. OA is the most common form of joint disease, with the majority of the 
population over 65 years of age demonstrating radiographic evidence of OA in at least one 
joint. Likewise, around two- thirds of the adult population suffer from LBP at some point in 
their lifetime. LBP is also a major cause of disability and suffering globally (Grabias and 
Mankin, 1979; Jackson, 2004). LBP OA and RA are important causes of disability and are 
increasingly among the ageing population. LBP is also common among younger athletes 
and those older individuals who enjoy sports such as golf (Baker and Patel, 2005; McHardy 
and Pollard, 2005; Reed and Wadsworth, 2010). 
The current inadequacy of treatments for these conditions, combined with their increasing 
prevalence exacerbates the burden on healthcare systems. Therefore, researchers and 
clinicians are striving for novel, innovative treatment options and the emergence of the 
fields of tissue engineering and regenerative medicine offer hope that long-term tissue 
repair may be possible. However, one of the current limiting factors for treatment of joint 
diseases is a source of cells. While a range of cell sources have been proposed, adult 
mesenchymal stem cells (MSCs) offer the greatest potential for clinical application. 
Many studies have explored the prevalence of arthritis (OA and RA), related 
musculoskeletal conditions, LBP and intervertebral disc degeneration among elderly 
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population. Chronic LBP is a major complaint of elderly patients and restricts most of their 
activities (with a higher prevalence in women). Interestingly LBP increases with age in men 
to reach the same frequency as women in those aged 90 years or older. Many studies have 
shown that a major cause of LBP is intervertebral disc degeneration, which is, primarily, an 
ageing related phenomenon. Degeneration of the intervertebral disc impacts not only on the 
disc, but also on the surrounding tissues such as the muscles and ligaments and affects the 
spine’s ability to cope with the physiologically normal loads it experiences during a daily 
routine. As well as accelerating degeneration these changes also cause pain and reduce 
the mobility of the spine. The drug treatments currently available for LBP are inadequate 
and restricted to symptomatic pain control in mild cases and complicated and invasive 
surgical intervention (i.e. discectomy or spinal fusion) in severe cases. The increasing 
prevalence of LBP among the ageing population will become a major socioeconomic issue 
as it exacerbates the burden on healthcare systems throughout the developed world. 
Therefore new treatments are needed which restore full disc function and normalise disc 
cell biology. 
5. Regenerative medicine for RA and OA 
Bone and cartilage defects are common features of joint diseases, such as RA and OA (Noel 
et al., 2002). They have significant social and economic impact on the aging population. 
Despite progress in orthopaedic surgery, bone and cartilage repair is a major challenge as 
large defects will not spontaneously heal (Noel et al., 2002). Regenerative medicine is an 
emerging field that seeks to repair or replace injured tissues and organs through natural or 
bioengineered means. Recent research on stromal MSCs has provided a new and exciting 
opportunity for bone and cartilage tissue engineering. We have learned a great deal about the 
isolation, cultivation, and characterization of MSCs in recent years. A huge amount of research 
effort is now focused on their differentiation and models that exploit their regenerative 
potential. MSCs have generated a great deal of public, scientific, and media interest because of 
their potential use in regenerative medicine and tissue engineering (Tolar et al., 2010). 
6. Structure and function of articular cartilage 
Cartilage is a flexible and mechanically compliant connective tissue found at the end of long 
bones in articulating joints and in the intervertebral disc. It is sub-classified into three 
different types: elastic cartilage, hyaline cartilage and fibrocartilage, which differ in the 
relative amounts of its three principal components, namely collagen fibres, ground 
substance (proteoglycans) and elastic fibres. Articular or hyaline cartilage is a load-bearing 
tissue with unique biological characteristics (Figure 2). The biochemical properties of 
cartilage depend on the structural design of the tissue, the molecular composition of the 
extracellular matrix (ECM) that makes up the bulk of the tissue volume and the interactions 
between its resident cells and the ECM (Buckwalter and Mankin, 1998). Chondrocytes are 
the only cells found within the cartilage ECM. They are architects of cartilage (Muir, 1995), 
building the macromolecular framework of its ECM from three distinct classes of 
macromolecules: collagens (predominantly type II collagens), proteoglycans (mainly 
aggrecan), and a variety of non-collagenous proteins. Collagens type II, IX, and XI form a 
fibrillar meshwork that gives cartilage tensile stiffness and strength (Buckwalter and 
Mankin, 1998; Eyre, 2004; Kuettner et al., 1991), whereas collagen type VI forms part of the 
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matrix immediately surrounding the chondrocytes, enabling them to attach to the 
macromolecular framework of the ECM and act as a transducer of biomechanical and 
biochemical signals in the articular cartilage (Guilak et al., 2006; Roughley and Lee, 1994). 
Large aggregating proteoglycans (aggrecan) are embedded in the ECM and give cartilage its 
stiffness to compression, its resilience and contribute to its long-term durability (Dudhia, 
2005; Kiani et al., 2002; Luo et al., 2000; Roughley and Lee, 1994). Figure 3 illustrates the 
major molecular components of the cartilage ECM. 
 
 
Fig. 2. A section of porcine articular cartilage showing the superficial, middle, deep and 
calcified zones 
ECM proteins in cartilage are of great significance for the regulation of the cell behaviour, 
proliferation, differentiation and morphogenesis (Enomoto-Iwamoto et al., 1997; Gonzalez et 
al., 1993; Hewitt et al., 1982; Kosher and Church, 1975; Kosher et al., 1973; Ramachandrula et 
al., 1992; Ruoslahti and Reed, 1994; Sommarin et al., 1989; von der Mark et al., 1977). Small 
proteoglycans, including decorin, biglycan, and fibromodulin are further embedded in the 
ECM. Decorin and fibromodulin both interact with the type II collagen fibrils in the matrix 
and play a role in fibrillogenesis and interfibril interactions. Biglycan is mainly found in the 
immediate surrounding of the chondrocytes, where it may interact with collagen type VI 
(Buckwalter and Mankin, 1998; Roughley and Lee, 1994). Modulation of the ECM proteins is 
regulated by an interaction of a diversity of growth factors with chondrocytes (Hunziker et 
al., 1994; Isgaard, 1992; Jenniskens et al., 2006; Sah et al., 1994; Trippel et al., 1989). In fact, it 
has been reported recently, that IGF-I and TGF-ǃ stimulate the chondrocyte surface 
expression of integrins, and that this event is accompanied by increasing adhesion of 
chondrocytes to matrix proteins (Loeser, 1997). Other non-collagenous proteins in articular 
cartilage such as cartilage oligomeric matrix protein (COMP) are less well studied and may 
have a value as a biomarker of turnover and degeneration of cartilage (Di Cesare et al., 
1996), while tenascin and fibronectin influence interactions between the chondrocytes and 
the ECM (Buckwalter and Mankin, 1998; Burton-Wurster et al., 1997). The ECM surrounds 
chondrocytes and protects them from biomechanical stress arousing during normal joint 
motion, determines the types and concentrations of molecules that reach the cells and helps 
to maintain the chondrocyte phenotype.  
www.intechopen.com
From Multipotent Cells to Fully Differentiated Connective Tissue Cells  
for Regenerative Medicine: Emerging Applications of Mesenchymal Stem Cells 
 
89 
 
Fig. 3. Molecular composition of the extracellular matrix (ECM) of articular cartilage 
Throughout life, cartilage undergoes continuous internal remodelling as chondrocytes 
replace matrix macromolecules lost through degradation. Evidence indicates that ECM 
turnover depends on the ability of chondrocytes to detect alterations in the 
macromolecular composition and organization of the matrix, including the presence of 
degraded macromolecules, and to respond by synthesizing appropriate types and 
amounts of new ECM components. It is known that mechanical loading of cartilage 
creates mechanical, electrical, and physicochemical signals that help to direct the 
synthesizing and degrading activity of chondrocytes (Mobasheri et al., 2002). In addition, 
the ECM acts as a signal transducer for chondrocytes (Millward-Sadler and Salter, 2004). 
A prolonged and severe decrease in the use of the joint leads to alterations in the 
composition of the ECM and eventually to a loss of tissue structure and its specific 
biomechanical properties, whereas normal physical strain stimulates the synthesizing 
activity of chondrocytes and possibly the internal tissue remodelling (Buckwalter and 
Lane, 1997; Maffulli and King, 1992). 
Although articular cartilage can tolerate a tremendous amount of intensive and repetitive 
physical stress, it manifests a striking inability to heal even the most minor injury 
(Buckwalter, 2003; Buckwalter and Lane, 1997; Martin et al., 2004; Newman, 1998). This 
makes joints particularly sensitive to degenerative processes (Solursh, 1991). Furthermore, 
aging leads to alterations in the ECM composition and alters the activity of the 
chondrocytes, including their ability to respond to a variety of stimuli such as growth 
factors (Eckstein et al., 2001; Hudelmaier et al., 2001; Ralphs and Benjamin, 1994). All these 
alterations increase the probability of cartilage degeneration (Buckwalter, 2003; Poole, 1999; 
Sarzi-Puttini et al., 2005; Setton et al., 1999) and emphasize the importance of interaction of 
chondrocytes with their surrounding ECM since this interaction regulates their growth, 
differentiation, and survival in normal and pathophysiological conditions such as OA 
(Shakibaei et al., 1999). 
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7. Identification and application of Adult Stem Cells 
There are two types of stem cells: embryonic stem cells and non-embryonic "somatic" or 
"adult" stem cells. Embryonic stem cells are found in the blastocyst whereas adult stem cells 
are found in adult tissues. Adult stem cells maintain the normal turnover of organs with a 
high intrinsic regenerative capacity. These include blood, skin and intestinal epithelium. 
Adult stem cells can be found in children, adolescents as well as adults and are generally 
unipotent or multipotent. Pluripotent adult stem cells are very rare and are generally found 
in small numbers. However, they can be found in a number of tissues including umbilical 
cord blood. The best studied adult stem cells are multipotent and are generally referred to 
by their tissue origin (i.e. haematopoietic stem cells that differentiate into erythrocytes, 
white blood cells, platelets, etc. and bone marrow stromal cells also known as MSCs which 
have the capacity to differentiate into connective tissue cells (Pittenger et al., 1999) (see 
Figure 4). 
 
 
Fig. 4. Differentiation potential of human mesenchymal stem cells 
These connective tissues include bone (Arinzeh, 2005; Hong et al., 2006; Noel et al., 2002), fat 
(Barry and Murphy, 2004; Helder et al., 2007), cartilage (Barry and Murphy, 2004; Caplan, 
2007; Noel et al., 2002), intervertebral disc (Richardson et al., 2007; Trubiani et al., 2005; 
Trubiani et al., 2006), ligament (Sonoyama et al., 2006; Trubiani et al., 2005; Trubiani et al., 
2006) and muscle (Barry and Murphy, 2004). Evidence suggests that these cells are also 
capable of differentiation along myogenic and neurogenic lineages, although these 
pathways are not normally utilised to demonstrate multipotentiality of isolated MSCs. 
Adult mesenchymal stem cells were originally isolated from bone marrow in 1999 by 
Pittinger and co-workers, who demonstrated their multilineage differentiation potential 
(Pittenger et al., 1999). Subsequent studies have identified the presence of stem cells in a 
number of adult tissues, including adipose, muscle, dermis, periosteum, synovial 
membrane, synovial fluid and articular cartilage. Thus far MSC-like progenitor cells have 
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been isolated from bone marrow (Grigoriadis et al., 1988), periosteum, trabecular bone, 
adipose tissue, synovium, skeletal muscle and deciduous teeth (Barry and Murphy, 2004; 
Sonoyama et al., 2006). In fact they were known as marrow stromal cells long before they 
were known as MSCs (Grigoriadis et al., 1988). The International Society for Cellular 
Therapies has recently proposed a definiton for MSCs (Dominici et al., 2006). While there are 
no definitive markers of MSCs a range of cell surface markers are routinely used as markers 
of MSCs. These include immunopositivity for STRO-1, CD73, CD105, CD106 CD145 and 
CD166, combined with negative immunoreactivity for CD11b, CD31, CD34, CD45 and 
CD117. These markers can also be used to identify a more homogeneous population of cells 
than previous methods utilising either density-gradient centrifugation, or even simple 
plastic adherence. The general heterogeneity of bone marrow cell populations can lead to 
variable results; however MSCs are generally regarded to be capable of differentiation along 
the chondrogenic, osteogenic and adipogenic pathways. Work from our laboratories 
suggests that MSCs are capable of differentiation to nucleus pulposus (NP) cells of the IVD, 
chondrocytes and osteoblasts (Csaki et al., 2009; Csaki et al., 2007; Mobasheri et al., 2009; 
Richardson et al., 2007). However, since definite markers of NP cells have only recently been 
described (Minogue et al., 2010), a range of chondrocyte markers, with which they share a 
large phenotypic similarity, are routinely used (see Figure 5 and Table 1 for details of some 
of the currently investigated MSC markers). 
 
 
Fig. 5. Positive expression of CD 90 and lack of expression of CD 34 in canine mesenchymal 
stem cells 
8. Proliferation of research on Adult Stem Cells 
Since they were first identified by Pittinger and co-workers (Pittenger et al., 1999) research 
on adult stem cells has proliferated at a staggering pace. Work using adult stem cells does 
not involve many of the ethical challenges associated with using embryonic stem cells. 
Another reason for the rapid expansion in this area is the availability of a range of adult 
tissues from humans and animals. MSCs also posses neuroprotective (Uccelli et al., 2011) 
and cardioregenerative (Flynn and O'Brien, 2011) properties as well as the potential for 
musculoskeletal regeneration (O'Sullivan et al., 2011). 
CD 90(+) CD 34(-)
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Cell surface markers Species Source 
Positive Negative 
Human Adipose tissue CD13, CD29, CD44, CD73 and 
CD90 
 
Canine Bone marrow CD90 and MHC-I CD34, CD45 and MHC-II 
Human Bone marrow 
Umbilical cord 
blood 
Adipose tissue 
CD29, CD44, CD73, CD90, 
CD105, CD106 and HLA-I 
CD14, CD34, CD45, CD133,  
CD144 and HLA-II 
Equine Bone marrow CD90, fibronectin, perlecan and 
collagen type IV 
--- 
Equine Umbilical cord 
matrix 
CD54, CD90, CD105, CD146, 
Oct4, SSEA-4, c-Kit, SSEA-3 and 
TRA-1-60 
CD34, CD45 and CD133 
Canine Bone marrow CD90 and CD105 CD34 and CD45 
Equine Umbilical cord 
blood 
Oct4, TRA-1-60, TRA-1-81 and 
SSEA-1 
___ 
Equine Adipose tissue Oct4, TRA-1-60 and TRA-1-81 SSEA-1 and SSEA-4 
Ovine Bone marrow CD44, vimentin and CD105 CD34 and CD45  
Human Adipose tissue CD44, CD90, CD105, CD146, 
CD166 and STRO-1  
CD14, CD31 and CD45 
Human Bone marrow CD44, CD90, CD105 and CD166 CD45 and CD117 
Human Bone marrow CD29, CD44, CD73, CD90, CD105 
and CD146 
CD14, CD34 and CD45 
Human Infrapatellar fat 
pad 
CD13, CD29, CD44, CD90, CD105 
and 3G5 
CD34 CD56, LNGFR and 
STRO-1  
Human Infrapatellar fat 
pad 
CD13, CD29, CD44, CD90 and 
CD105 
CD35, CD56, LNGFR and 
STRO-1 
Human Infrapatellar fat 
pad 
CD13, CD29, CD44, CD90 and 
CD105 
CD34, CD56, LNGFR and 
STRO-1 
Ovine Bone marrow CD29, CD44 and CD166 CD31 and CD45 
Human Bone marrow CD44c, CD54, CD90 and STRO-1 CD14 and CD45 
Human Placental 
chorionic villi 
CD49a/VLA-1, CD146, CD106, 
3G5, ǂ-SMA and STRO-1 
X63 and vWF 
Canine Adipose tissue CD29, CD44 and CD90 CD13, CD31, CD34, CD45, 
CD73, CD105 and CD117 
Canine Umbilical cord 
blood 
CD29, CD33, CD44, CD105, 
CD184 and Oct4 
CD4, CD8a, CD10, CD14, 
CD20, CD24, CD31, CD34, 
CD38, CD41a, CD41/61, 
CD62p, CD73, CD90, CD133 
and HLA-DR 
Equine Bone marrow Sox-2, Oct4 and Nanog CD34 
Equine Adipose tissue CD90 and CD44 CD13 
Canine Adipose tissue CD44, CD90, CD140a and CD117 CD34 and CD45 
Canine Adipose tissue CD90 and CD105 CD34 and CD45 
Table 1. Cell surface markers of MSCs from various species and tissue sources.  
Data from Penny et al., (in press) 
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9. Musculoskeletal tissue regeneration 
Connective tissues, such as bone, cartilage, tendon, ligament and the IVD all suffer from 
both traumatic and age-related degenerative injuries. While bone repairs relatively well, the 
avascular and hypocellular nature of cartilage and in particular the IVD means these tissues 
suffer from a very limited self-repair capacity. During OA and IVD degeneration (one of the 
main causes of LBP) there is an imbalance between synthesis and degradation of the extra-
cellular matrix which leads to an overall loss of tissue. This tissue destruction over time 
leads to pain and reduced mobility. While the increased repair capacity of bone prevents 
this, a number of metabolic and degenerative disorders, such as osteoporosis, osteonecrosis 
and Paget’s disease, can cause bone loss or abnormal bone turnover. Traumatic injury and 
loss of bone following surgery for other diseases such as cancer can also lead to bone lesions 
which are too large for the body’s self-regeneration capacity to cope with. Current clinical 
interventions for large bone defects, such as bone grafting, suffer from problems with donor 
site morbidity and limited material for large scale autologous grafts and infection or 
immune rejection with allogeneic grafts. The main histological, ECM and phenotypic 
markers of osteoblasts, chondrocytes and adipocytes differentiated from mesenchymal stem 
cells are shown in Table 2. 
 
 Osteoblasts Chondrocytes Adipocytes 
Alizarin Red Toluidine Blue Oil Red O 
Alcian Blue 
Safranin O 
Histological 
Stains von Kossa 
Masson trichrome 
stain C 
 
Type I collagen Type II collagen Type I collagen ECM Markers 
Beta 1 integrin Aggrecan Beta 1 integrin 
Alkaline phosphatase (ALP) Sox9 Adiponectin 
Osteonectin (OSTN) 
Osteocalcin (OCN) 
 Peroxisome proliferator-
activated receptor- 
gamma (PPAR-gamma) 
Runt-related transcription 
factor-2 (Runx2) / Core 
binding factor alpha 1 
 Fatty Acid Binding 
Protein 4 (FABP4) 
Osteopontin (OPN)  Lipoprotein Lipase (LPL) 
Bone Sialoprotein (BSP) 
Vitamin D receptor (VDR) (14)
Other 
Markers 
Homeobox gene MSX2 (14) 
 Leptin 
Table 2. The main histological, ECM and phenotypic markers of osteoblasts, chondrocytes and 
adipocytes differentiated from mesenchymal stem cells. Data from Penny et al., (in press) 
These limitations in current clinical treatments for bone defects and disorders have led to the 
development of tissue engineering strategies using both synthetic and natural scaffold 
implants. Materials such as tricalcium phosphates (Guo et al., 2004a; Guo et al., 2004b; Jiang 
et al., 2007; Shao et al., 2006; Solchaga et al., 1999), calcium carbonates (Kreklau et al., 1999), 
hydroxyapatite (Chajra et al., 2008; Reddi, 2000; Yoshikawa and Myoui, 2005) and Bioglass 
(Helen and Gough, 2008; Wilda and Gough, 2006) have all been utilised alongside growth 
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factors to promote new growth, or act as supports for implanted cells to regenerate new 
tissue. These materials all aim to mimic the specialised microenvironment or bone and 
cartilage and are growing in their clinical application. 
Articular cartilage and the IVD share similarities in cellular phenotype and extra-cellular 
matrix composition. Consequently similar approaches have been adopted for tissue 
engineering cartilage and IVD (Kalson et al., 2008; Richardson et al., 2007). As with bone 
repair, there are major limitations to current clinical treatments for OA and IVD 
degeneration. Scaffold-free autologous chondrocyte implantation (ACI) is currently used 
clinically to treat small cartilage lesions, such as those caused by traumatic injury. For this 
treatment a biopsy is taken from a non-load bearing region of cartilage, the chondrocytes 
enzymatically extracted, expanded in monolayer culture, then reimplanted into the lesion 
and covered with a periosteal flap (Brittberg et al., 1994). The therapy has been used to treat 
over 12,000 patients worldwide and offers cartilage repair and reduced pain equivalent to 
existing surgical cartilage repair therapies (Peterson et al., 2002). However, while this 
treatment appears to work well for small cartilage lesions it has limited practical application 
for larger osteoarthritic lesions. 
Cell implantation into degenerate IVDs has been demonstrated in animal models to both 
inhibit degeneration and regenerate tissue (Ganey et al., 2003). A small-scale study in 
human patients comparing standard discectomy for disc prolapse with discectomy plus 
autologous disc cell implantation demonstrated improvements in pain reduction, 
preservation of disc height and prevention of adjacent disc segment degeneration in patients 
who underwent the cell implantation therapy (Meisel et al., 2006; Meisel et al., 2007). 
Clinical follow-up data is limited and there is no biochemical or biomechanical data, but this 
study demonstrates the potential for cell-based therapies for IVD tissue regeneration. 
However, studies suggest that isolation of cells from degenerate IVD could accelerate 
degeneration, while isolation of cells from non-degenerate levels may induce degenerative 
changes and needle puncture is a common method of inducting degeneration in animal 
models of disease (Kim et al., 2005; Korecki et al., 2008; Masuda et al., 2006; Zhang et al., 
2009). Additionally, as IVD degeneration, like OA in cartilage, affects the phenotype of 
resident cells the identification of a suitable cell source for novel tissue engineering and 
regenerative medicine strategies is one of the key determinants of its success. 
Cells used in tissue engineering must survive within the graft site and produce a suitable 
and functional matrix, which mimics, or even improves on the original tissue. Autologous 
chondrocyte implantation (ACI) has been shown to be effective in the treatment of 
osteoarthritic cartilage lesions, producing a type II collagen and proteoglycan-rich matrix 
which restores function to the joint (Gillogly et al., 1998). Similarly, implantation of 
chondrocytes within a 3-dimensional carrier system such as a collagen gel has also been 
shown to produce a cartilaginous matrix, which could be of clinical use (Gavenis et al., 2006; 
Sakai et al., 2006). 
10. Microenvironmental challenges for MSC-based tissue regeneration:  
The 3-D environment and oxygenation 
One of the major challenges facing MSC-based tissue engineering is mimicking and 
recreating the microenvironment of the tissue that is being regenerated. MSCs destined for 
tissue engineering must be able to survive in a physiologically harsh extracellular matrix, an 
environment that will be highly hypoxic, acidic, and nutrient deprived. In addition, this 
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environment may be exposed to dynamic compressive forces or rich in pro-inflammatory 
mediators that could induce catabolic and apoptotic responses in MSCs. Culturing the cells 
in a high-density 3-D environment is a good starting point and clearly has a number of 
benefits. High-density culture (see Figure 6) is a 3-dimensional system that has been in the 
literature since the early 1970’s. High-density suspension cultures of chondrocytes were 
initially used to study cartilage matrix protein synthesis by mammalian chondrocytes 
(Kuettner et al., 1982a; Kuettner et al., 1982b), specifically mucoprotein (Nevo and Dorfman, 
1972) and proteoglycan (Handley and Lowther, 1976) biosynthesis. In an important study 
published in 1977 the method was refined by von der Mark and von der Mark who used 
tissue culture plastic dishes on an agar base to monitor chondrogenesis of stage-24 chick 
limb mesodermal cells in vitro by analyzing the onset of type II collagen synthesis (von der 
Mark and von der Mark, 1977). This work demonstrated that high-density cultures may be 
used for the analysis of cell specific types of collagen and provide a useful model for 
detailing the specific events in the differentiation of mesenchymal cells in vitro. Several 
subsequent studies used chick limb bud mesenchymal cells and chick sternal chondrocytes 
cultured in high-density to study chondrogenesis and proteoglycan synthesis (Lohmander 
et al., 1979) and fibronectin expression (Hassell et al., 1979). We have used this culture 
system as a model for chondrogenic, osteogenic and tenogenic differentiation of MSCs and 
redifferentiation of dedifferentiated chondrocytes (Csaki et al., 2009; Csaki et al., 2007; 
Seifarth et al., 2009; Shakibaei et al., 2006) (see Figure 7). The high-density model exhibits a 
number of characteristics that make it particularly suitable for studied on chondrogenesis. In 
the first 24 hours of the high-density chondrocyte culture, cells form prechondrogenic areas 
composed of densely packed cells with intercellular interactions (gap junctions); these are 
surrounded by a perichondrium of flat fibroblast-like cells (Shakibaei et al., 1993) 
resembling the situation during the early stage of chondrogenesis in vivo. The extensive cell-
cell interactions during the first step of chondrogenesis are crucial for cell aggregation 
(Denker et al., 1999; Loty et al., 2000). The high-density culture system allows investigations 
during chondrogenesis starting from early blastema/mesenchymal stem cell condensations 
until cartilage maturation. This chondrogenic development is accompanied by enlargement 
of cartilage nodules, which is not due to cell proliferation but rather is due to appositional 
growth, which includes the transition of perichondral cells into chondrocytes. These 
conclusions are based on the almost complete absence of mitotic figures in cartilage and 
perichondrium and on the continuous increase in nodule size during cultivation (Denker et 
al., 1999). 
In addition to 3-D environment, the presence of member(s) of the transforming growth 
factor (TGF-ǃ) family and low oxygen tension have been reported to promote the in vitro 
differentiation of MSCs (Ronziere et al., 2010). Appropriate levels of oxygenation can be 
powerful determinants of MSC differentiation. For example, low oxygen tension is a more 
potent promoter of chondrogenic differentiation than dynamic compression (Meyer et al., 
2010). Enhanced chondrogenic differentiation of human bone marrow-derived MSCs has 
been observed in a low oxygen environment in micropellet cultures (Khan et al., 2010; 
Markway et al., 2010). Clearly oxygen tension is an important determinant of MSC 
differentiation; hypoxia, cell aggregation and TGF-ǃ delivery are crucial for achieving 
complete chondrogenesis (Mobasheri et al., 2009; Richardson et al., 2007). Although MSCs 
may possess a superior potential to generate a functional repair tissue in low oxygen 
tensions, in the context of in vitro cartilage tissue engineering, cells maintained in normoxic 
conditions in the presence of TGF-ǃ generate the most mechanically functional tissue 
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(Buckley et al., 2010). Physiologically low oxygen tension during monolayer expansion of 
MSCs has been shown to be advantageous in order to improve cartilage tissue engineering 
in a sheep model (Zscharnack et al., 2009). The information available in the literature leads 
to the conclusion that MSCs in culture function optimally in an atmosphere of reduced 
oxygen that more closely approximates documented in vivo oxygen tension (Lennon et al., 
2001). These observations apply to cells derived from OA patients (Khan et al., 2007). Clearly 
fine adjustments to these conditions in future studies could produce an engineered tissue 
with the desirable mechanical and biological properties. 
 
 
Fig. 6. 3-Dimensional high-density culture of mesenchymal stem cells (MSCs) and primary 
chondrocytes. The MSCs in this high-density model are stimulated to undergo 
chondrogenesis by the co-cultured primary chondrocytes 
 
 
Fig. 7. 3-Dimensional high-density culture. In this model chondrocytes (C) are maintained in 
a pellet at the air-liquid interface, which will allow them to maintain their phenotype and 
produce an extracellular matrix (M). Cells at the periphery form a perichondrium-like layer 
of cells (P) 
One proposed method to ensure MSC survival and function following implantation into the 
degenerate tissue is to pre-condition, or pre-differentiate the cells. A recent study by Wuertz 
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and co-workers (Wuertz et al., 2008) demonstrated that when cultured in an intervertebral 
disc-like environment containing low glucose, low pH and high osmolarity, MSCs 
demonstrated a lower proliferation rate and lower expression of matrix genes compared to 
standard conditions, highlighting the importance of the microenvironmental niche on MSC 
biology. In particular, low pH has been shown to inhibit expression of aggrecan by MSCs 
(Wuertz et al., 2009a), while the presence of catabolic cytokines IL-1ǃ and TNF- , which are 
increased in both disc degeneration and OA, inhibited chondrogenesis of MSCs (Wehling et 
al., 2009). 
11. High density cultures of MSCs: “3Rs” models for engineering biomimetic 
models of articular cartilage 
A number of animal models of arthritis have been developed to study arthritic disease 
pathogenesis and evaluate the efficacy of candidate anti-inflammatory and anti-arthritic 
drugs for clinical development (Aigner et al., 2010; Ameye and Young, 2006; Brandt, 1991, 
1994; Goldring, 1999; Koch and Betts, 2007; van den Berg, 2001). These animal models may 
involve injection of inflammatory agents into the joint, surgical creation of joint instability or 
surgical replication of joint trauma. Such models not only cause a considerable amount of 
pain and suffering but also none of them have a proven track record of predictability in 
human disease. Consequently, there is an acute need for developing novel and alternative in 
vitro models that mimic the biology of cartilage (Freed et al., 2006; Oreffo and Triffitt, 1999; 
Reddi, 1998, 2000; Sittinger et al., 2004). Many studies have used articular cartilage and 
synovial tissues to establish in vitro models of the joint. In our laboratories we have 
developed explant models of articular cartilage inflammation, co-cultures of primary 
synoviocytes and chondrocytes as well as 3-dimensional high-density cultures of 
chondrocytes and MSCs (Buhrmann et al., 2010; Csaki et al., 2009; Csaki et al., 2007; 
Mobasheri et al., 2009; Richardson et al., 2010). We have also determined the potential of 
phytochemicals as stimulators of chondrogenic differentiation. These culture models of 
MSCs, fully differentiated cells and co-cultures have potential of as ‘‘proof of principle’’ 
ethically acceptable ‘‘3Rs’’ models for engineering biomimetic models of articular cartilage 
in vitro for the purpose of replacing and reducing the use of animals in arthritis research. 
This approach could help reduce the number of laboratory animals used in arthritis research 
and may provide a realistic alternative to experimental animals. 
12. Conclusions 
One of the major conceptual difficulties in designing or applying clinically based MSC 
therapies to cartilage and intervertebral disc degeneration is the complexity and 
heterogeneity of disease among patients. New information obtained from in vitro studies 
and animal models are useful. However, the information gained from some animal models 
cannot be interpolated directly for translational studies in human patients with cartilage or 
disc degeneration. For example, stem cell therapy may not be applied across the entire 
spectrum of cartilage and intervertebral disc degeneration; the therapy may well work in 
cases that involve very early morphological and degenerative changes but success may not 
be guaranteed in cases where the damage and degeneration is extensive. It is difficult to 
conceive how MSCs and tissue engineering may be clinically useful in extreme cases where 
the cartilage has completely worn away or the disc has collapsed completely. Therefore, the 
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variability among the human patient population complicates the concept of stem cell based 
therapy and introduces a very large element of risk, which may inhibit or impede the 
translational potential of regenerative medicine using MSCs. 
Several clinical trials have already begun to evaluate the use and efficacy of mesenchymal 
stem cells and biomaterials in arthritic diseases of joints and the spine. At the present time 
too many gaps remain, both clinically and scientifically, before such approaches can be used 
safely and rationally. Interest in tissue engineering of cartilage and intervertebral disc is 
increasing and cartilage tissue engineering has been investigated for over 20 years. 
However, none of the approaches available for cartilage for example have been able to 
achieve the consistency, effectiveness and reliability required for clinical applications. Tissue 
engineering of a mechanically resilient disc that meets the structural and functional criteria 
for effective functional integration into a defect site in the host is a difficult endeavour. One 
of the fundamental weaknesses of all the tissue engineered models available to date is that 
none of them possess the normal zonal organization of cells that is seen in vivo (i.e. annulus 
fibrosus and nucleus pulposus regions) and the local composition of extracellular matrix in 
each zone. This structural organisation is a pre-requisite for normal disc function and the 
success of any future clinical applications. 
For the foreseeable future the molecular determinants of MSC differentiation into 
chondrogenic and osteogenic lineages continue to be elucidated using existing 2D models. 
However, new research using 3D models is more likely to shed light on fundamental 
processes such as paracrine-mediated differentiation, and mechanisms responsible for the 
recruitment of endogenous progenitor populations in response to chemical, biological, and 
physical cues. Furthermore, three-dimensional and high-density culture models have huge 
potential as ‘‘3Rs’’ models for replacing and reducing the use of animals in arthritis 
research. There are numerous animal models for OA and other types of arthritis. However, 
none of them have a proven track record of predictability for the equivalent disease in 
humans and the majority of them are plagued with problems. Three-dimensional culture 
conditions, hypoxia and the use of specially supplemented culture media will ultimately 
need to be assessed in pre-clinical animal models that closely mimic the human disease. 
However, 3D culture models utilizing tissue engineered articular cartilage and IVD should 
help us carry out better and more focused research as well as reducing the number and 
variety of experimental animals used before moving onto larger and more expensive pre-
clinical animal models. 
Bone marrow and adipose tissue derived MSCs possess the potential for chondrogenic, 
osteogenic and tenogenic differentiation in the presence of appropriate cellular stimuli. 
Stable induction can be achieved with a combination of endocrine and environmental 
factors (i.e. co-culture of MSCs and primary cells), or through culturing MSCs with spent 
media from primary chondrocyte, osteoblast or tendon cell cultures. Therefore, these results 
point to new ways in which MSCs might be manipulated in culture for future therapeutic 
strategies for cartilage, bone and tendon tissue engineering. 
Regenerative medicine relies on the optimistic view that stem cells, allogeneic tissue 
transplantation, patient derived adult stem cells and biomaterials may be used for repairing 
and regenerating tissues and organs in the future. Although we should maintain this 
optimistic view, it would be prudent to consider the numerous hurdles and complicating 
factors that need to be overcome as research progresses in this exciting and rapidly 
expanding field. 
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